Pal; Kollol

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pal; Kollol.The latest application filed is for "5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo [1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer".

Company Profile

1.7.17

Pal; Kollol - Needham MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo [1,5-a]pyrimidine Derivatives And Related Compounds As Trk Kinase Inhibitors For Treating Cancer App 20220235055 - Pal; Kollol ; et al.	2022-07-28
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]p- yrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer Grant 11,230,546 - Pal , et al. January 25, 2	2022-01-25
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]p- Yrimidine Derivatives And Related Compounds As Trk Kinase Inhibitors For Treating Cancer App 20210094956 - PAL; Kollol ; et al.	2021-04-01
Compositions, Dosages, And Methods Of Using Tetrahydrocannabinol Derivatives App 20170022179 - Tepper; Mark ; et al.	2017-01-26
RecA inhibitors with antibiotic activity, compositions and methods of use Grant 9,155,792 - Cottarel , et al. October 13, 2	2015-10-13
Compositions, Dosages, And Methods Of Using Tetrahydrocannabinol Derivatives App 20130338220 - Tepper; Mark ; et al.	2013-12-19
Therapeutic compound and treatments Grant 8,088,785 - Llompart , et al. January 3, 2	2012-01-03
Compounds Useful For Treating Neurodegenerative Disorders App 20110136749 - Findeis; Mark A. ; et al.	2011-06-09
Compounds Useful For Treating Neurodegenerative Disorders App 20110136750 - Findeis; Mark A. ; et al.	2011-06-09
Compounds useful for treating neurodegenerative disorders Grant 7,851,641 - Findeis , et al. December 14, 2	2010-12-14
Compositions And Methods For Potentiating Antibiotic Activity App 20100234348 - Cottarel; Guillaume ; et al.	2010-09-16
Therapeutic Compound And Treatments App 20100137253 - Llompart; Javier ; et al.	2010-06-03
Reca Inhibitors With Antibiotic Activity, Compositions And Methods Of Use App 20100029597 - Cottarel; Guillaume ; et al.	2010-02-04
Therapeutic compound and treatments Grant 7,652,029 - Llompart , et al. January 26, 2	2010-01-26
Compositions And Methods For Antibiotic Potentiation And Drug Discovery App 20090264342 - Cottarel; Guillaume ; et al.	2009-10-22
Compounds useful for treating neurodegenerative disorders App 20070010503 - Findeis; Mark A. ; et al.	2007-01-11
Therapeutic compound and treatments App 20060014770 - Llompart; Javier ; et al.	2006-01-19
Therapeutic agents, methods, and treatments App 20040266732 - Galvez, Jorge ; et al.	2004-12-30
Method of identifying inhibitors of CDC25 App 20020183249 - Taylor, Neil R. ; et al.	2002-12-05
Methods for forming combinatorial libraries using reductive amination App 20020115106 - Shipps, Gerald W. ; et al.	2002-08-22
Methods for forming combinatorial libraries combining amide bond formation with epoxide opening App 20020077491 - Shipps, Gerald W. ; et al.	2002-06-20
Inhibitors of cyclin dependent kinases Grant 5,733,920 - Mansuri , et al. March 31, 1	1998-03-31

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.